You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. FULCRUM THERAPEUTICS INC

Fulcrum Therapeutics Inc XNAS: FULC

Fulcrum Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Momentum Trap
Download real time

3.65 0.19 (5.49%)

63.97% Fall from 52W High

582.1K XNAS Volume

XNAS 22 Apr, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share

Fulcrum Therapeutics Inc Key Metrics

Select

Market Capitalization

Below industry Median
197

PE TTM

Negative PE TTM
-20.3

PEG TTM

Negative PEG TTM
-0.2

Price to Book

Below industry Median
0.8

Institutional holding current Qtr %

High in industry
96.8

Revenue Growth Qtr YoY %

Negative Revenue Growth Qtr YoY %
-100

Operating Revenue growth TTM %

High in industry
2,752

Net Profit Qtr Growth YoY %

Below industry Median
33.1

Net Profit TTM Growth %

High in industry
90

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-24.8

Piotroski Score

Below industry Median
3

Rel Perf vs Sector quarter%

-8.2

ROE Annual %

Negative ROE Annual %
-4.1

RoA Annual %

Negative RoA Annual %
-3.8
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Low Financial Strength
27.8 / 100
Valuation Score
Expensive Valuation
23.5 / 100
Momentum Score
Technically Neutral
47.8 / 100
Momentum Trap These stocks are the ones with poor quality and also financials and technical ranging from bad to medium score. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM
Analyst Price Target
6
1Yr Price target upside is 55%
6 analysts

22

S

8

W

1

O

2

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Fulcrum Therapeutics Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '22Dec '23Dec '24Dec '25Dec '26050100Actual RevenueAvg. Estimate
Miss

Fulcrum Therapeutics Inc's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

Current EPS
-0.2
Avg. Estimate
-1.2
Low Estimate
-1.4
High Estimate
-1
Current EPS
Avg. Estimate
Miss

EPS is expected to reduce by 650.0% in FY25

Consensus Recommendation

7 ANALYST Recommendations
HOLD

Created with Highcharts 7.2.21Sell4Hold1Buy1Strong Buy

The consensus recommendation from 7 analysts for Fulcrum Therapeutics Inc is HOLD

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Fulcrum Therapeutics Inc Stock Analysis

Fulcrum Therapeutics Inc stock analysis with key metrics, changes, and trends.

Fulcrum Therapeutics Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$80 M2752.05%positive

Annual Revenue rose 2,752.05%, in the last year to $80 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

Annual Net Profit$9.72 M90.01%positive

Annual Net Profit rose 90.01% in the last year to $9.72 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

Price to Earning Ratio-20.26-negative

Price to Earning Ratio is -20.26, which is negative.

Stock Price$3.65-46.64%negative

Stock Price fell 46.64% and underperformed its sector by 55.79% in the past year.

Quarterly Net profit$16.57 M33.07%positive

Quarterly Net profit rose 33.07% YoY to $16.57 M. Its sector's average net profit growth YoY for the quarter was -41.97%.

Debt to Equity Ratio0.04-positive

Debt to Equity Ratio of 0.04 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-4.07 %-4.07%negative

Return on Equity(ROE) for the last financial year was -4.07%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding29.76 %-1.29%negative

Mutual Fund Holding decreased by 1.29% in the last quarter to 29.76.

Promoter Share Holding3.54 %0%neutral

Promoter Share Holding stayed the same in the most recent quarter at 3.54%.

VIEW LESS


Loading data..

Fulcrum Therapeutics Inc - Company Profile

What does Fulcrum Therapeutics Inc do?

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Fulcrum Therapeutics Inc Management structure

All Gross Remunerations are in USD
Mr. Alan A. Musso
Chief Financial Officer and Treasurer
-
2024
Gross Remuneration
Year
Mr. Alex C. Sapir
Director, President and Chief Executive Officer
-
2024
Gross Remuneration
Year
Mr. Gregory Tourangeau
Vice President, Finance, Controller and Principal Accounting Officer
-
2024
Gross Remuneration
Year

Fulcrum Therapeutics Inc Board of directors

All Gross Remunerations are in USD
Mr. Colin Hill
Independent Director
-
2024
Gross Remuneration
Year
Dr. James J. Collins, PhD
Independent Director
-
2024
Gross Remuneration
Year
Ms. Rachel King
Independent Director
-
2024
Gross Remuneration
Year
Mr. James A. Geraghty
Independent Director
-
2024
Gross Remuneration
Year
Dr. Robert J. Gould, PhD
Director
-
2024
Gross Remuneration
Year
Ms. Katina Dorton, J.D.,M.B.A.
Independent Director
-
2024
Gross Remuneration
Year

Fulcrum Therapeutics Inc FAQ

How is Fulcrum Therapeutics Inc today?
Fulcrum Therapeutics Inc today is trading in the green, and is up by 5.49% at 3.65.
Fulcrum Therapeutics Inc is currently trading up 5.49% on an intraday basis. In the past week the stock rose 25.00%. stock has been down -8.75% in the past quarter and fell -46.64% in the past year. You can view this in the overview section.